A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
Astellas Pharma Inc
AbbVie
AstraZeneca
Tesaro, Inc.
Trishula Therapeutics, Inc.
AbbVie
GlaxoSmithKline
Eli Lilly and Company
Pfizer
Genentech, Inc.
Takeda
Merck Sharp & Dohme LLC
GlaxoSmithKline
GlaxoSmithKline
Ohio State University Comprehensive Cancer Center
AbbVie
GlaxoSmithKline
Lixte Biotechnology Holdings, Inc.
Progen Pharmaceuticals
Achieve Life Sciences
Boehringer Ingelheim
Boehringer Ingelheim
University of Southern California
AEterna Zentaris
Synta Pharmaceuticals Corp.
Sanofi
Amgen
GlaxoSmithKline
Centocor, Inc.
Pfizer
Agennix
Sanofi
Adherex Technologies, Inc.
Case Comprehensive Cancer Center
SCRI Development Innovations, LLC